GLAXOSMITHKLINE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLAXOSMITHKLINE, and when can generic versions of GLAXOSMITHKLINE drugs launch?
GLAXOSMITHKLINE has one hundred and forty-nine approved drugs.
There are thirty-two US patents protecting GLAXOSMITHKLINE drugs.
There are seven hundred and sixteen patent family members on GLAXOSMITHKLINE drugs in fifty-nine countries and one hundred and eighty-eight supplementary protection certificates in twenty countries.
Summary for GLAXOSMITHKLINE
International Patents: | 716 |
US Patents: | 32 |
Tradenames: | 104 |
Ingredients: | 90 |
NDAs: | 149 |
Drug Master File Entries: | 8 |
PTAB Cases with GLAXOSMITHKLINE as petitioner: | See PTAB cases with GLAXOSMITHKLINE as petitioner |
Drugs and US Patents for GLAXOSMITHKLINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | WELLCOVORIN | leucovorin calcium | INJECTABLE;INJECTION | 089465-001 | Jan 23, 1989 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Glaxosmithkline | CEFTIN | cefuroxime axetil | FOR SUSPENSION;ORAL | 050672-001 | Jun 30, 1994 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-003 | Sep 15, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Glaxosmithkline | TOTACILLIN | ampicillin/ampicillin trihydrate | CAPSULE;ORAL | 060060-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GLAXOSMITHKLINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 209482-001 | Sep 18, 2017 | RE44874 | ⤷ Subscribe |
Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-001 | Jun 1, 1994 | 4,466,972 | ⤷ Subscribe |
Glaxosmithkline Llc | FLOLAN | epoprostenol sodium | INJECTABLE;INJECTION | 020444-002 | Sep 20, 1995 | 4,338,325 | ⤷ Subscribe |
Glaxosmithkline | ZYBAN | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020711-002 | May 14, 1997 | 5,427,798 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 6 mg/0.5 mL, 0.5 mL vials | ➤ Subscribe | 2004-10-25 |
➤ Subscribe | Tablets | 0.25 mg, 0.5 mg, 1 mg and 2 mg | ➤ Subscribe | 2004-12-22 |
➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2007-10-31 |
➤ Subscribe | Tablets | 62.5 mg/25 mg | ➤ Subscribe | 2010-09-14 |
➤ Subscribe | Extended-release Capsules | 225 mg and 425 mg | ➤ Subscribe | 2006-10-11 |
➤ Subscribe | Extended-release Tablets | 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg | ➤ Subscribe | 2014-02-12 |
➤ Subscribe | Extended-release Tablets | 8 mg | ➤ Subscribe | 2008-11-03 |
➤ Subscribe | Extended-release Tablets | 12 mg | ➤ Subscribe | 2009-02-05 |
➤ Subscribe | Extended-release Tablets | 6 mg | ➤ Subscribe | 2009-07-22 |
➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2007-10-30 |
➤ Subscribe | Orally Disintegrating Tablets | 25 mg, 50 mg, 100 mg, and 200 mg | ➤ Subscribe | 2009-12-21 |
➤ Subscribe | Injection | 6 mg/0.5 mL, 0.5 mL (prefilled syringes) | ➤ Subscribe | 2006-05-09 |
➤ Subscribe | Tablets | 3 mg, 4 mg and 5 mg | ➤ Subscribe | 2005-02-04 |
➤ Subscribe | Tablets | 250 mg/100 mg | ➤ Subscribe | 2009-04-03 |
➤ Subscribe | Extended-release Capsules | 325 mg | ➤ Subscribe | 2006-11-07 |
➤ Subscribe | Oral Suspension | 750 mg/5 mL | ➤ Subscribe | 2009-10-20 |
➤ Subscribe | Extended-release Tablets | 4 mg | ➤ Subscribe | 2008-10-31 |
➤ Subscribe | Extended-release Tablets | 3 mg | ➤ Subscribe | 2009-01-08 |
➤ Subscribe | Extended-release Tablets | 2 mg | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Extended-release Tablets | 3 mg | ➤ Subscribe | 2009-01-08 |
International Patents for GLAXOSMITHKLINE Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hungary | E041427 | ⤷ Subscribe |
Canada | 2493078 | ⤷ Subscribe |
Cyprus | 2014043 | ⤷ Subscribe |
Australia | 2018246214 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for GLAXOSMITHKLINE Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1633724 | 596 | Finland | ⤷ Subscribe | |
1633724 | 13/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
1740177 | PA2014038 | Lithuania | ⤷ Subscribe | PRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428 |
1740177 | C20140032 00132 | Estonia | ⤷ Subscribe | PRODUCT NAME: UMEKLIDIINBROMIID;REG NO/DATE: EU/1/14/922 30.04.2014 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.